Company Profile
Eloxx Pharmaceuticals
Company Overview
Eloxx Pharmaceuticals, Inc. is a clinical-stage Rare Disease biopharmaceutical company focused on restoring production of essential proteins depleted due to genetic mutations. Our library of novel drug candidates enable read-through of premature stop codons and have shown dose dependent improvements in restoring essential protein functions across multiple disease areas. Our lead investigational product candidate, ELX-02 has been granted Orphan Disease designation and is advancing to Phase 2 in Cystic Fibrosis and Cystinosis. Our recently announced Inherited retinal disease program and our partnership with the Foundation Fighting Blindness has created an opportunity to advance additional library compounds into clinical development. We anticipate continuing our rapid growth as the Company advances in clinical development, enters additional therapeutic areas and expands our pipeline.
Eloxx Pharmaceuticals (ELOX) is a Nasdaq listed biotechnology company headquartered in Boston MA with regional operations in New Jersey, Pennsylvania and Tel Aviv Israel.